#hmpv

[healthywealthysouls]

Human Metapneumovirus (HMPV) - Dangers, Precautions, and Protection

Human metapneumovirus (HMPV) is a respiratory virus that affects people of all age groups. First identified in the Netherlands in 2001, HMPV has gained recognition as a significant cause of respiratory tract infections worldwide. In this article, we will delve into the nature of HMPV, its potential dangers, and essential precautions individuals can take to prevent its spread.

click here to read full article

[politikwatch]

Gefährliches #Virus: Ist das humane Metapneumovirus (#hMPV) Noch existiert kaum eine Behandlungsmethode, geschweige denn eine Impfung. Dennoch sei ein Testen auf das humane Metapneumovirus sinnvoll, findet der Arzt.

[covid-chaos-corruption]

COMMENTS:

mdlstone1959    

No one can trust or believe anything the CDC says. They are liars. Sadly they have destroyed the truth, therefore our trust in them as well. Thanks Jobama for destroying America.

terrygonder   

Here’s another scare tactic from the CDC. Their mRNA vaccine has most likely been the cause of any immunity issues in this country and around the world. If the CDC says something is a problem, they most likely caused it. If they say a vaccine is needed, run the other way.

[health-prohive]

What is human metapneumovirus (HMPV)?

Ans.-

There are most of people don't know about metapneumo virus , and what is cause and symptoms so today we know overall about HMPV

Human metapneumovirus (HMPV) is  discover in 2001,Human metapneumovirus are aspiratory virus that can cause an upper respiratory infection (like a cold) or a lower respiratory infection (like bronchitis or pneumonia). It is most see in children but can also affect adults. Read More

[thejewishlink]

Infections With Little-Known Virus Explode, CDC Warns

A respiratory virus that most people have never heard of was to blame for many hospitalizations and illnesses this spring, health officials say. The human metapneumovirus, or HMPV, causes symptoms similar to COVID-19 or RSV, but doctors don’t usually test for it outside of a hospital setting, meaning many people likely had no idea they had it. The Centers for Disease Control and Prevention…

[jcsmicasereports]

Emerging infectious agents: an unusual case of Metapneumovirus pneumonia in an adult patient by Graziana Francesca Greco in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

Human Metapneumovirus (hMPV), a relatively new virus, is a common cause of acute respiratory infection, especially common in the pediatric population. Despite hMPV infection in adults is possible, this rarely results in serious clinical manifestation. Here, we describe a hypoxemic respiratory failure related to pneumonia in an adult patient in whom hMPV was detected in respiratory samples.

Keywords

Human Metapneumovirus; SARS-CoV-2; Covid-19.

CASE HISTORY

A 61-yr-old caucasian man presented to the Emergency Department (ASST Mantua Hospital, Mantua, Italy) with fever up to 39°C, poorly responsive to antipyretics, nocturnal dyspnea and productive cough with mucus-purulent sputum for three days. On physical examination he appeared in good general condition, collaborating and oriented. The following parameters were recorded: blood pressure 140/90mmHg, heart rate of 100 beats min-1; respiratory rate of 23 breaths min-1; and body temperature of 38.4°C. His arterial oxygen saturation on room air was 87%. Chest examination revealed abnormal breath sounds with rhonchi and fine crackles in the middle lobe and inferior lobes bilaterally, no wheezes were heard. Laboratory findings revealed lymphocytosis (81000 x 103/µl), low platelet count (113000 x 106/µl) and an increase in alanine transaminase value (59 U/L), total bilirubin value (1.13 mg/dL) and CPR value (112 mg/L). Room air arterial blood gas analysis showed a normocapnic hypoxemia: pH 7.43, carbon dioxide tension 40.5 mmHg, oxygen tension 60.4 mmHg, and HCO3 24 mmol L-1. The  SARS-CoV-2 antigen detection test on nasopharyngeal swab was negative. A chest radiograph showed multiple, small, patchy opacities in the right upper and middle lobe and  no pleural effusion was observed. Based on these findings he was admitted to the Respiratory Department.

His medical history included chronic lymphocytic leukemia in follow-up which did not require any specific treatment. He denied taking any medications or to be a smoker, he drinks a glass of wine once a day and has no known allergies. The patient was a farmer who cultivates wheat and maize but he had no animal exposure and no travel history in the last few years. There is no family history or childhood history of respiratory complaints. He was vaccinated with three dosesagainst the SARS-CoV-2 infection (Pfizer) but not against the influenza virus.

Based on the patient’s presentation and testing results, on suspicion of bacterial pneumonia he was empirically treated with IV Piperacillin/Tazobactam, the patient required oxygen support at 3L min-1 and an inhalation therapy with Beclomethasone/Formoterol was set up ex adiuvantibus. In the following days, several microbiological investigations were carried out to determine the etiology of pneumonia: blood culture, urinoculture, sputum culture, Legionella, Haemofilus and Pneumococcus serologic tests, Legionella pneumophila and Pneumococcal urinary antigen test, all of which were negative.

A  nasopharyngeal swab FilmArray Respiratory Panel Assay (NP FARP) was then requested: it was positive for human Metapneumovirus and the result was confirmed by repeating the test. For non responder fever and further increase of CPR (230 mg/l) and PCT (0.27 ng/ml), Levofloxacin and later Meropenem were added in the perspective of a resistant bacterial etiology.  On  the 6th hospitalization day a chest computed tomography (CT) scan was obtained (Figures 1 and 2) which demonstrated large opacities with gradient borders, distributed in the peribronchial area at the right upper lobe, middle lobe and both the lower lobes; they tended to the confluence configuring parenchymal consolidations with aerial bronchogram at the level of the cost-phrenic angle. Imaging also showed bilateral hilar and mediastinal lymphadenopathy (max diameter 3.4 x 2 cm), splenomegaly and absence of pleural effusion. Blood chemistry tests for HIV, Aspergillus antigen and galactomannan were also investigated but turned out negative. To rule out other infectious agents the patient underwent bronchoscopy with bronchoalveolar lavage (BAL) into the middle lobe. BAL provides material for various microbiological and cytological tests: Gram stain, culture, Koch’s bacillus DNA, Galactomannan, Cytomegalovirus and P. Jirovecii and immunological analysis were negative. From respiratory virus panel on BAL only human Metapneumovirus was isolated, this unique microbiological data was according to the NP FARP’s result,  thus supporting and confirming the new hypothesis of a viral pneumonia in an adult patient with probable secondary mild immunosuppression due to his hematological disease. About ten days after entering the ward, there was a gradual decrease of CPR and a progressive improvement in clinical conditions and respiratory function to allow the suspension of oxygen therapy. At the end of hospitalization, pulmonary function tests were performed and showed a restrictive syndrome (FEV1/FVC 76.2, TLC 68% and VC 79% of predicted) and mild reduction of diffusion capacity (DLCO 62% and KCO 99%), probably representing the residual functional impairment due to viral pneumonia. The patient finally suspended all therapies and at discharge was referred for a one-month follow-up visit.

DISCUSSION

Human Metapneumovirus (hMPV), a relatively new virus first discovered in 2001, has been detected in 4-16% of patients with acute respiratory infections [1] [2] [3]. In particular, a recent review of 48 previous articles, including 100,151 patients under the age of five hospitalized for CAP, identified this virus as a cause of pneumonia in 3.9% of patients [4]. A recent study of 1386 hospitalized adult patients identified hMPV pneumonia in only 1.64%, indicating that it was much less common than in the infant population [5]. Metapneumovirus causes disease primarily in infants, but rarely can infect immunosuppressed individuals and elderly as well. Seroprevalence studies have shown that 90-100% of 5-10 years old children have previous infection [6]. Reinfection can occur during adulthood because of defected immunity acquired during the first contact with hMPV and/or because of different viral genotypes. The incubation period varies widely but is typically 3-5 days. The disease severity depends on the patient's condition and it ranges from mild upper airway infection to life-threatening pneumonia or bronchiolitis [7]. Clinically, Metapneumovirus infection is often indistinguishable from RSV infection, particularly in the pediatric population, and common symptoms include hypoxemia, cough, fever, upper and lower airway infections and wheezing [8]. hMPV infant patients are often hospitalized  for bronchiolitis and pneumonia [9]. In young adults, a flu-like syndrome with fever may occur in a small number of instances, but infection in geriatric subjects may cause severe clinical manifestations such as pneumonia and, in rare cases, death [10].

As described in this case, it was not surprising that antibiotics and corticosteroids were administered in most patients infected with Metapneumovirus mainly for two reasons: in most cases the specific diagnostic tests for hMPV are not carried out at admission and/or physicians prefer to continue steroid and antibiotic treatment to control potential unidentified bacterial infections in patients in which no etiological agent had been identified associated with hMPV infection. The overuse of these drugs could therefore be reduced through the adoption at admission of specific diagnostic tests for such etiological agent, especially if specific risk factors are present (age, immunodepression, etc.). In addition, the adoption of such tests could reduce the nosocomial spread of this virus, allowing an early isolation of the infected patient [11].

Conflicts of interest: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. Funding: The authors report no involvement in the research by the sponsor that could have influenced the outcome of this work.

Authors’ contributions : All authors contributed equally to the manuscript and read and approved the final version of the manuscript.

[ms-hells-bells]

somewhat ill, desperately manifesting for it to disappear overnight, because i already used 3 of my 5 sick days (you go up to 10 gained a year once the first anniversary passes, but the first year is 5) just a couple weeks ago when i caught the HMPV going around.

[crazevil]

차세대 백신 혁명: Vicebio의 1억 달러 투자 유치와 미래 전망

1억 달러 투자 유치! Vicebio가 만드는 차세대 호흡기 바이러스 백신의 미래

안녕하세요, 여러분! 오늘은 영국의 바이오텍 스타트업 Vicebio가 1억 달러 규모의 시리즈 B 투자를 유치했다는 기쁜 소식을 전해드리려고 합니다. Vicebio는 차세대 호흡기 바이러스 백신 개발을 목표로 하고 있으며, 이는 많은 사람들이 기대하는 혁신적인 프로젝트입니다. 그럼, 이 흥미로운 이야기를 자세히 살펴보도록 하죠!

Vicebio의 차세대 백신, 무엇이 특별할까요?

Vicebio는 최신 기술을 활용해 호흡기 바이러스에 대한 새로운 백신을 개발하는 데 주력하고 있습니다. 이번 투자로 회사는 특히 RSV(호흡기세포융합바이러스)와 hMPV(인간메타뉴모바이러스)를 타겟으로 한 백신 VXB-241의 임상 1상 시험을 지원할 예정입니다.

시선 강탈: '모뽀클램프' 기술

백신 개발의 핵심은 '모뽀클램프(molecular clamp)' 기술입니다. 이 기술은 호주의 퀸즐랜드 대학 연구진이 개발한 것으로, 바이러스 표면의 단백질을 "잠금"��여 바이러스가 세포에 부착되기 전에 이를 고정하는 방식입니다. 이를 통해 강력한 면역 반응을 유도할 수 있으며, 제조 공정도 간소화되어 백신의 비용 효율성이 높아집니다.

투자 라운드의 주요 참여자

이번 투자 라운드는 TCGX가 주도했으며, 골드만삭스(Goldman Sachs Alternatives), Avoro Ventures, venBio, Uniquest와 창립 투자자 Medicxi도 참여했습니다. 이들은 모두 Vicebio의 비전과 기술력에 큰 기대를 걸고 있습니다.

더 나아가기: 미래 프로젝트와 경쟁 상황

Vicebio는 이번 투자금으로 VXB-241 외에도 다른 호흡기 바이러스 백신을 개발할 계획입니다. 특히, PIV3(파라인플루엔자 바이러스 3형)까지 포함한 복합 백신을 개발하여 더 많은 바이러스에 대한 보호막을 제공하고자 합니다.

하지만 경쟁도 만만치 않습니다. AstraZeneca가 최근 인수한 Icosavax가 이미 RSV와 hMPV를 동시에 타겟으로 하는 백신의 임상 2상에 돌입한 상황입니다. 이에 대해 Vicebio는 2025년 중반까지 임상 결과를 기대하고 있습니다.

끝맺으며

Vicebio의 이번 투자 유치는 그들이 차세대 호흡기 바이러스 백신 시장에서 중요한 역할을 할 것임을 보여줍니다. 이들이 이끄는 혁신적인 기술과 접근법이 많은 사람들의 건강을 지켜주는 큰 도움이 되기를 기대해봅니다. 앞으로도 Vicebio의 발전과 성과를 눈여겨보며 응원하겠습니다.

여러분의 생각은 어떠신가요? 댓글로 남겨주세요. 이 이야기가 흥미로웠다면, 공유도 잊지 마세요!

감사합니다. 💉🌟

[delveinsight12]

Bronchiolitis Market: Overview, Causes, Symptoms, Diagnosis, and Treatment

Bronchiolitis is a common respiratory condition primarily affecting infants and young children, characterized by inflammation of the small airways in the lungs (bronchioles). This condition often leads to significant respiratory distress and is a major cause of hospitalization in infants during the winter months. This article provides a comprehensive overview of bronchiolitis, including its causes, symptoms, diagnostic methods, and treatment options.

Bronchiolitis is an acute viral infection that causes inflammation and swelling of the bronchioles, the smallest air passages in the lungs. The condition is most prevalent in children under two years of age and typically occurs in the winter and early spring. Bronchiolitis is usually caused by respiratory syncytial virus (RSV), but other viruses can also be involved. The severity of bronchiolitis can range from mild to severe, with some cases requiring hospitalization.

Causes of Bronchiolitis

The primary cause of bronchiolitis is viral infection, with several key viruses implicated:

1. Respiratory Syncytial Virus (RSV): RSV is the most common cause of bronchiolitis, accounting for the majority of cases. It is highly contagious and spreads through respiratory droplets.

2. Rhinoviruses: These viruses, commonly associated with the common cold, can also cause bronchiolitis, especially in combination with other pathogens.

3. Parainfluenza Viruses: These viruses can contribute to respiratory infections in children, including bronchiolitis.

4. Adenoviruses: Adenoviruses can also cause bronchiolitis, although they are less common than RSV.

5. Human Metapneumovirus (hMPV): This virus can cause respiratory infections similar to those caused by RSV and is increasingly recognized as a cause of bronchiolitis.

Signs and Symptoms

The symptoms of bronchiolitis typically develop within a few days after exposure to a virus and may include:

1. Cough: A persistent cough is a common symptom of bronchiolitis, often accompanied by wheezing and a rattling sound in the chest.

2. Wheezing: The inflammation of the bronchioles causes narrowing of the airways, leading to a wheezing sound during breathing.

3. Respiratory Distress: Infants may show signs of difficulty breathing, including rapid or shallow breathing, nasal flaring, and use of accessory muscles to breathe.

4. Fever: Mild to moderate fever may accompany bronchiolitis, although high fever is less common.

5. Runny or Stuffy Nose: Initial symptoms often include a runny or congested nose, which may progress to more severe respiratory symptoms.

6. Decreased Appetite: Infants with bronchiolitis may have a reduced appetite and difficulty feeding due to respiratory distress.

7. Cyanosis: In severe cases, the skin or lips may turn bluish, indicating inadequate oxygenation and requiring urgent medical attention.

Diagnosis of Bronchiolitis

Diagnosing bronchiolitis involves a combination of clinical evaluation and diagnostic tests:

1. Medical History and Physical Examination: A healthcare provider will assess the patient's medical history and perform a physical examination. Key signs include respiratory distress, wheezing, and abnormal lung sounds.

2. Chest X-Ray: While not always necessary, a chest X-ray can help rule out other conditions such as pneumonia or congenital heart defects. It may show hyperinflation of the lungs or other signs consistent with bronchiolitis.

3. Viral Testing: Diagnostic tests, such as polymerase chain reaction (PCR) or immunofluorescence assays, can identify the specific virus causing the infection. RSV is often confirmed using these methods.

4. Blood Tests: Blood tests may be performed to assess the severity of the infection, check for signs of dehydration, or rule out other conditions.

5. Oxygen Saturation Monitoring: Pulse oximetry is used to measure blood oxygen levels, helping to assess the severity of respiratory distress.

Treatment of Bronchiolitis

Treatment for bronchiolitis focuses on supportive care and alleviating symptoms, as there is no specific antiviral treatment for the condition. Management strategies include:

1. Supportive Care: 

   - Hydration: Ensuring adequate fluid intake is crucial to prevent dehydration, especially if the child is experiencing reduced appetite or difficulty feeding.

   - Nasal Saline Drops: Saline nasal drops or sprays can help relieve nasal congestion and improve breathing.

   - Humidified Air: Using a cool-mist humidifier can help ease respiratory symptoms by keeping the airways moist.

2. Medications:

   - Bronchodilators: Medications such as albuterol may be used to relax the airways and ease wheezing, although their effectiveness in bronchiolitis is debated.

   - Corticosteroids: These are generally not recommended for routine use in bronchiolitis, but they may be prescribed in severe cases or when there is evidence of underlying asthma.

3. Oxygen Therapy: For infants with low oxygen levels, supplemental oxygen may be administered to ensure adequate oxygenation.

4. Hospitalization: In severe cases, hospitalization may be required to provide intensive monitoring and supportive care, including intravenous fluids, respiratory support, and close observation.

5. Preventive Measures:

   - RSV Prophylaxis: In high-risk infants, such as those with congenital heart disease or premature birth, a medication called palivizumab may be given as a preventive measure during RSV season.

Bronchiolitis Market Insights

The market for bronchiolitis treatments reflects the ongoing need for effective management strategies and innovations in respiratory care:

- Market Size and Growth: The global market for bronchiolitis treatments is expanding, driven by the prevalence of respiratory infections in children and the development of new therapeutic and diagnostic solutions. Key segments include pharmaceuticals, diagnostic tools, and supportive care products.

- Key Players: Leading companies involved in the bronchiolitis market include:

   - GlaxoSmithKline: Known for its respiratory therapies and involvement in the development of treatments for respiratory conditions in children.

   - Roche Holdings: Engaged in diagnostics and research related to respiratory infections, including bronchiolitis.

   - AstraZeneca: Focuses on respiratory medicines and has a presence in the market for managing respiratory infections.

   - Novartis Pharmaceuticals: Contributes to research and development in respiratory and infectious disease therapies.

- Research and Development: Ongoing research aims to improve understanding of bronchiolitis, develop new antiviral agents, and enhance supportive care strategies. Innovations in diagnostics and treatments are expected to contribute to better management and outcomes for affected children.

Bronchiolitis is a common and often challenging respiratory condition that affects infants and young children. Understanding its causes, symptoms, and treatment options is crucial for effective management and improved outcomes. With ongoing research and advancements in the field, there is hope for more effective therapies and better preventive measures. The growing market for bronchiolitis treatments highlights the importance of continued innovation and support for managing this prevalent and impactful condition.

Download sample report @ https://www.delveinsight.com/sample-request/bronchiolitis-market

[vibrantgroup9]

OVARIAN CYST

Ovarian cysts are fluid-filled sacs that develop in a woman’s ovaries. While most cysts are harmless and go away on their own, some can cause more serious health issues, especially if left untreated. In some cases, ovarian cysts can be related to certain genes, such as the HMPV gene. Studies have found that certain genetic mutations, like the HMPV gene, may be associated with an increased risk…

[kmp78]

“Nana's smart, she gave him some heavy antibiotics, so he's completely knackered and peacefully snoozing away “. -Nana can’t get anything to give him that a doctor or the like didn’t prescribe. Though I do hope he is sleeping soundly for health’s sake, antibiotics don’t make you sleepy and he called what he has just a “virus” and a “cold”. Antibiotics aren’t properly prescribed for that. (Though I think he’s probably got a little more than a simple, random virus and hMPV or RSV are likely nasty culprits.) Anyway, I think that what ever medications he is taking, I think K’s version of his approach to care is quite possible and probably will work the very best!!! 🤭

Meds are all fine and well, but they won't save his throat/voice if he destroys them. 🤷🏼‍♀️

[decentralvaccine]

Astra Zeneca Agrees To Purchase RSV Vaccine Maker For $1.1B

AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Icosavax is developing a combination vaccine candidate targeting RSV and human metapneumovirus (hMPV). RSV is a leading cause of pneumonia in toddlers and the elderly, while hMPV causes very similar respiratory tract infections.

The cash deal aimed at bolstering AstraZeneca's drugs pipeline values U.S.-listed Icosavax at $15 a share, plus up to $5 a share if certain milestones are met.

AstraZeneca made its first foray into vaccines by co-developing the COVID-19 shot with Oxford University. It set up a separate vaccine and antibody therapy division in late 2021.

https://finance.yahoo.com/news/1-astrazeneca-buy-rsv-vaccine-071944311.html

[rnomics]

Viruses, Vol. 15, Pages 2272: Human Metapneumovirus-Induced Host #microRNA Expression Impairs the Interferon Response in Macrophages and Epithelial Cells

Human metapneumovirus (HMPV) is a nonsegmented, single-stranded negative #RNA virus and a member of the Pneumoviridae family. During HMPV infection, macrophages play a critical role in defending the respiratory epithelium by secreting large amounts of type I interferon (IFN). Micro#RNAs (#miRNAs) are small, noncoding, single-stranded #RNAs that play an essential role in regulating gene expression during normal cellular homeostasis and disease by binding to specific #mRNAs, thereby regulating at the transcriptional and post-transcriptional levels with a direct impact on the immune response and other cellular processes. However, the role of #miRNAs in macrophages and respiratory viral infections remains largely unknown. Here, we characterized the susceptibility of THP-1-derived macrophages to HMPV infection and the effect of hsa-miR-4634 on these cells. Transfection of an #miRNA mimic and inhibitor demonstrated that hsa-miR-4634 regulates the IFN response in HMPV-infected macrophages, suggesting that HMPV induces the expression of the #miRNA as a subversion mechanism of the antiviral response. This effect was not limited to macrophages, as a similar effect was also observed in epithelial cells. Overall, our results demonstrate that hsa-miR-4634 is an important factor in regulating the IFN response in macrophages and epithelial cells during HMPV infection. https://www.mdpi.com/1999-4915/15/11/2272?utm_source=dlvr.it&utm_medium=tumblr